Most Recent
Sparke Helmore has refuted allegations by IOOF subsidiary Australian Executor Trustees (SA) that it failed to provide proper legal advice to the trustee on a 2012 pine plantation sale that left 4,500 investors without millions of dollars worth of assets.
IOOF subsidiary Australian Executor Trustees (SA) is facing an $82 million claim for compensation by investors angered by the way the trustee handled the sale of a 42,000 hectare timber plantation run by collapsed forestry giant Gunns Group.
Landowners above the Sydney Metro underground tunnel will be allowed to claim compensation before construction is complete, with a court also preparing to consider potential compensation for any reduced development potential.
A judge has allowed the applicant in a class action over allegedly dangerous combustible cladding to sue a German-based cladding manufacturer, saying there was a prima facie case the company violated the Australian Consumer Law.
Debt collector ACM Group has been hit with a $750,000 fine for engaging in unconscionable conduct by misleading, harassing and coercing two vulnerable customers while chasing unpaid debts.
The consumer watchdog has sought more than $1.5 million in penalties against debt collector ACM Group after the company was found liable for harassing vulnerable customers, but a judge on Tuesday questioned whether the fine, which could leave the company insolvent, was too punitive.
The defendants in a shareholder class action over QRxPharma's alleged failure to disclose problems with regulatory approval for its painkiller Moxduo have won access to information on class members' financial brokers.
US-based Millennium Pharmaceuticals has secured a temporary injunction that bans generic drug maker Juno Pharmaceuticals from importing or selling its cheap version of breakthrough cancer drug Velcade in Australia.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy's Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.
Two patent infringement lawsuits have been launched over attempts to sell generic versions of breakthrough cancer drug Velcade in Australia, after a US court last year struck down attempts to invalidate a patent for the drug.